CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Autres langues Charles River Laboratories International, Inc. Berne S.E.

Actions

RV6

US1598641074

Recherche biotechnologique et médicale

Temps Différé Berne S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CHF	-.--%		-.--%	-

05/06	Charles River Laboratories pourrait surperformer au second semestre 2026, selon RBC	MT
03/06	Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM

Autres langues

05/06	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says
01/06	Charles River Laboratories to Present at William Blair and Jefferies Conferences
13/05	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing
13/05	Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions
13/05	Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
13/05	Charles River Laboratories and MEDIPOST Co., Ltd. Sign Non-Exclusive MOU to Collaborate on GMP-Compliant Testing and Commercial and Marketing Efforts
11/05	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors
11/05	Charles River Laboratories International, Inc. Announces Board Elections
11/05	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow
11/05	Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
08/05	Charles River Laboratories International, Inc. Seeks M&A Opportunities
08/05	Charles River Laboratories International : Quarterly Report for Quarter Ending March 28, 2026 (Form 10-Q)
07/05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.
07/05	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026
07/05	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance
07/05	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94
07/05	Charles River beats quarterly estimates on steady demand for drug development services
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M
07/05	Charles River Laboratories International : Q1 2026 Earnings Presentation
07/05	Charles River: Q1 Earnings Snapshot
07/05	Charles River Laboratories Announces First-Quarter 2026 Results
07/05	Charles River Laboratories International, Inc. Reports Consolidated Impairment Charges Results for the Quarter Ended March 28, 2026
07/05	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026